Forte Biosciences, Inc. (FBRX): Price and Financial Metrics
FBRX Price/Volume Stats
Current price | $0.70 | 52-week high | $1.29 |
Prev. close | $0.69 | 52-week low | $0.38 |
Day low | $0.67 | Volume | 52,700 |
Day high | $0.74 | Avg. volume | 34,746 |
50-day MA | $0.68 | Dividend yield | N/A |
200-day MA | $0.73 | Market Cap | 25.34M |
FBRX Stock Price Chart Interactive Chart >
Forte Biosciences, Inc. (FBRX) Company Bio
Forte Biosciences Inc. operates as a clinical-stage dermatology company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company is based in Torrance, California.
Latest FBRX News From Around the Web
Below are the latest news stories about FORTE BIOSCIENCES INC that investors may wish to consider to help them evaluate FBRX as an investment opportunity.
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing RulesDALLAS, December 01, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. |
Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business UpdateDALLAS, November 13, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2023 results and provided a business update. |
ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company’s Upcoming Annual MeetingNEW YORK, September 14, 2023--Camac Partners, LLC ("Camac") and ATG Capital Management, LLC ("ATG") (together with the other participants in their solicitation, the "Concerned Stockholders," the "Group" or "we"), which collectively own approximately 8.5% of the outstanding common stock of Forte Biosciences, Inc. (Nasdaq: FBRX) ("Forte" or the "Company"), today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co., LLC ("Gla |
Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company’s BoardroomNEW YORK, September 06, 2023--Camac Partners, LLC ("Camac") and ATG Capital Management, LLC ("ATG") (together with the other participants in their solicitation, the "Concerned Stockholders," the "Group" or "we") collectively own approximately 8.5% of the outstanding common stock of Forte Biosciences, Inc. (Nasdaq: FBRX) ("Forte" or the "Company"). Today, the Group and its independent director candidates – Michael Hacke and Chris McIntyre – responded to misrepresentations and distortions included |
Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to StockholdersNEW YORK, August 25, 2023--Camac Partners, LLC ("Camac") and ATG Capital Management, LLC ("ATG") (together with the other participants in their solicitation, the "Concerned Stockholders," the "Group" or "we"), who collectively own approximately 8.5% of the outstanding common stock of Forte Biosciences, Inc. (Nasdaq: FBRX) ("Forte" or the "Company"), today announced that they have filed a definitive proxy statement with the U.S. Securities and Exchange Commission (the "SEC") in connection with Fo |
FBRX Price Returns
1-mo | -2.78% |
3-mo | -14.81% |
6-mo | 5.74% |
1-year | -31.37% |
3-year | -86.95% |
5-year | -97.42% |
YTD | -14.81% |
2023 | -17.83% |
2022 | -53.27% |
2021 | -64.73% |
2020 | 355.24% |
2019 | -93.51% |
Loading social stream, please wait...